{"id":10804,"date":"2025-04-22T11:46:43","date_gmt":"2025-04-22T10:46:43","guid":{"rendered":"https:\/\/new.if-pan.krakow.pl\/?p=10804"},"modified":"2026-04-21T20:21:48","modified_gmt":"2026-04-21T19:21:48","slug":"serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza","status":"publish","type":"post","link":"https:\/\/if-pan.edu.pl\/en\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/","title":{"rendered":"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) &#8211;\u00a0II faza"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Celem projektu STEP7, jest rozw\u00f3j agonisty receptora 5-HT7 jako pierwszego w&nbsp;tej klasie leku na b\u00f3l neuropatyczny. Projekt, realizowany w&nbsp;latach 2020-2023 przez Konsorcjum Celon Pharma i&nbsp;Instytut Farmakologii im. Jerzego Maja PAN (Szybka \u015acie\u017cka, POIR.01.01.01-00-0887\/1), uzyska\u0142 dalsze finansowanie z&nbsp;programu Fundusze Europejskie dla Nowoczesnej Gospodarki (FENG 01.01-IP.01-1017\/23).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u0141\u0105czna warto\u015b\u0107 projektu: 61 839 406,21 PLN<br>Wydatki kwalifikowalne: 33 026 714,85 PLN<br>Wysoko\u015b\u0107 wk\u0142adu Funduszy Europejskich: 14 380 385,05 PLN<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&nbsp;W pierwszym etapie aktualnej fazy projektu zostan\u0105 wykonane prace przemys\u0142owe obejmuj\u0105ce przygotowanie odpowiedniej formy leku wraz z badaniami toksykologicznymi i&nbsp;farmakologii bezpiecze\u0144stwa. Nast\u0119pnie, po uzyskaniu pozwolenia na rozpocz\u0119cie bada\u0144 klinicznych, wykonane zostan\u0105 badania I fazy oraz badania typu \u201eproof-of-concept\u201d fazy IIa.<br>Sukces projektu pozwoli na dalszy rozw\u00f3j produktu innowacyjnego na skal\u0119 \u015bwiatow\u0105 wpisuj\u0105c si\u0119 w&nbsp;zakres wsparcia przewidziany w&nbsp;dzia\u0142aniu \u015acie\u017cka SMART w FENG i&nbsp;cel szczeg\u00f3\u0142owy w&nbsp;Priorytecie 1. FENG.<\/p>\n\n\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"92\" src=\"https:\/\/new.if-pan.krakow.pl\/wp-content\/uploads\/2025\/01\/feng-dofinansowane-przez-ue-celon-1024x92.png\" alt=\"\" class=\"wp-image-8201\" srcset=\"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/feng-dofinansowane-przez-ue-celon-1024x92.png 1024w, https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/feng-dofinansowane-przez-ue-celon-300x27.png 300w, https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/feng-dofinansowane-przez-ue-celon-768x69.png 768w, https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/feng-dofinansowane-przez-ue-celon.png 1178w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Celem projektu STEP7, jest rozw\u00f3j agonisty receptora 5-HT7 jako pierwszego w&nbsp;tej klasie leku na b\u00f3l neuropatyczny. Projekt, realizowany w&nbsp;latach 2020-2023 przez Konsorcjum Celon Pharma i&nbsp;Instytut Farmakologii im. Jerzego Maja PAN (Szybka \u015acie\u017cka, POIR.01.01.01-00-0887\/1), uzyska\u0142 dalsze finansowanie z&nbsp;programu Fundusze Europejskie dla Nowoczesnej Gospodarki (FENG 01.01-IP.01-1017\/23). \u0141\u0105czna warto\u015b\u0107 projektu: 61 839 406,21 PLNWydatki kwalifikowalne: 33 026 714,85 [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":8208,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[58],"tags":[],"class_list":["post-10804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-archiwum"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.4 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) -\u00a0II faza - Instytut Farmakologii PAN<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) -\u00a0II faza\" \/>\n<meta property=\"og:description\" content=\"Celem projektu STEP7, jest rozw\u00f3j agonisty receptora 5-HT7 jako pierwszego w&nbsp;tej klasie leku na b\u00f3l neuropatyczny. Projekt, realizowany w&nbsp;latach 2020-2023 przez Konsorcjum Celon Pharma i&nbsp;Instytut Farmakologii im. Jerzego Maja PAN (Szybka \u015acie\u017cka, POIR.01.01.01-00-0887\/1), uzyska\u0142 dalsze finansowanie z&nbsp;programu Fundusze Europejskie dla Nowoczesnej Gospodarki (FENG 01.01-IP.01-1017\/23). \u0141\u0105czna warto\u015b\u0107 projektu: 61 839 406,21 PLNWydatki kwalifikowalne: 33 026 714,85 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/\" \/>\n<meta property=\"og:site_name\" content=\"Instytut Farmakologii PAN\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-22T10:46:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-21T19:21:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/Projekt-bez-nazwy.png\" \/>\n\t<meta property=\"og:image:width\" content=\"940\" \/>\n\t<meta property=\"og:image:height\" content=\"788\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Magdalena Bartosik\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Magdalena Bartosik\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/\"},\"author\":{\"name\":\"Magdalena Bartosik\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#\\\/schema\\\/person\\\/6cf30bc4bc4eb96688ff1c7cbc34f8cc\"},\"headline\":\"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) &#8211;\u00a0II faza\",\"datePublished\":\"2025-04-22T10:46:43+00:00\",\"dateModified\":\"2026-04-21T19:21:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/\"},\"wordCount\":168,\"publisher\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/if-pan.edu.pl\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Projekt-bez-nazwy.png\",\"articleSection\":[\"Archiwum\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/\",\"url\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/\",\"name\":\"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) -\u00a0II faza - Instytut Farmakologii PAN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/if-pan.edu.pl\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Projekt-bez-nazwy.png\",\"datePublished\":\"2025-04-22T10:46:43+00:00\",\"dateModified\":\"2026-04-21T19:21:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#primaryimage\",\"url\":\"https:\\\/\\\/if-pan.edu.pl\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Projekt-bez-nazwy.png\",\"contentUrl\":\"https:\\\/\\\/if-pan.edu.pl\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Projekt-bez-nazwy.png\",\"width\":940,\"height\":788},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/archiwum\\\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/if-pan.edu.pl\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aktualno\u015bci\",\"item\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Aktualno\u015bci\",\"item\":\"https:\\\/\\\/if-pan.edu.pl\\\/aktualnosci\\\/najnowsze-aktualnosci\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) &#8211;\u00a0II faza\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#website\",\"url\":\"https:\\\/\\\/if-pan.edu.pl\\\/\",\"name\":\"Instytut Farmakologii PAN\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/if-pan.edu.pl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#organization\",\"name\":\"Instytut Farmakologii PAN\",\"url\":\"https:\\\/\\\/if-pan.edu.pl\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/if-pan.edu.pl\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/logo_ifpan.svg\",\"contentUrl\":\"https:\\\/\\\/if-pan.edu.pl\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/logo_ifpan.svg\",\"width\":539,\"height\":139,\"caption\":\"Instytut Farmakologii PAN\"},\"image\":{\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/if-pan.edu.pl\\\/#\\\/schema\\\/person\\\/6cf30bc4bc4eb96688ff1c7cbc34f8cc\",\"name\":\"Magdalena Bartosik\",\"url\":\"https:\\\/\\\/if-pan.edu.pl\\\/en\\\/institute\\\/employees\\\/magdalena-bartosik\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) -\u00a0II faza - Instytut Farmakologii PAN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/","og_locale":"en_US","og_type":"article","og_title":"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) -\u00a0II faza","og_description":"Celem projektu STEP7, jest rozw\u00f3j agonisty receptora 5-HT7 jako pierwszego w&nbsp;tej klasie leku na b\u00f3l neuropatyczny. Projekt, realizowany w&nbsp;latach 2020-2023 przez Konsorcjum Celon Pharma i&nbsp;Instytut Farmakologii im. Jerzego Maja PAN (Szybka \u015acie\u017cka, POIR.01.01.01-00-0887\/1), uzyska\u0142 dalsze finansowanie z&nbsp;programu Fundusze Europejskie dla Nowoczesnej Gospodarki (FENG 01.01-IP.01-1017\/23). \u0141\u0105czna warto\u015b\u0107 projektu: 61 839 406,21 PLNWydatki kwalifikowalne: 33 026 714,85 [&hellip;]","og_url":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/","og_site_name":"Instytut Farmakologii PAN","article_published_time":"2025-04-22T10:46:43+00:00","article_modified_time":"2026-04-21T19:21:48+00:00","og_image":[{"width":940,"height":788,"url":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/Projekt-bez-nazwy.png","type":"image\/png"}],"author":"Magdalena Bartosik","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Magdalena Bartosik","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#article","isPartOf":{"@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/"},"author":{"name":"Magdalena Bartosik","@id":"https:\/\/if-pan.edu.pl\/#\/schema\/person\/6cf30bc4bc4eb96688ff1c7cbc34f8cc"},"headline":"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) &#8211;\u00a0II faza","datePublished":"2025-04-22T10:46:43+00:00","dateModified":"2026-04-21T19:21:48+00:00","mainEntityOfPage":{"@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/"},"wordCount":168,"publisher":{"@id":"https:\/\/if-pan.edu.pl\/#organization"},"image":{"@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#primaryimage"},"thumbnailUrl":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/Projekt-bez-nazwy.png","articleSection":["Archiwum"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/","url":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/","name":"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) -\u00a0II faza - Instytut Farmakologii PAN","isPartOf":{"@id":"https:\/\/if-pan.edu.pl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#primaryimage"},"image":{"@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#primaryimage"},"thumbnailUrl":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/Projekt-bez-nazwy.png","datePublished":"2025-04-22T10:46:43+00:00","dateModified":"2026-04-21T19:21:48+00:00","breadcrumb":{"@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#primaryimage","url":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/Projekt-bez-nazwy.png","contentUrl":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2025\/01\/Projekt-bez-nazwy.png","width":940,"height":788},{"@type":"BreadcrumbList","@id":"https:\/\/if-pan.edu.pl\/aktualnosci\/archiwum\/serotoninergiczna-terapia-przeciwbolowa-oparta-o-agoniste-receptora-5-ht7-step7-ii-faza\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/if-pan.edu.pl\/en\/"},{"@type":"ListItem","position":2,"name":"Aktualno\u015bci","item":"https:\/\/if-pan.edu.pl\/aktualnosci\/"},{"@type":"ListItem","position":3,"name":"Aktualno\u015bci","item":"https:\/\/if-pan.edu.pl\/aktualnosci\/najnowsze-aktualnosci\/"},{"@type":"ListItem","position":4,"name":"Serotoninergiczna terapia przeciwb\u00f3lowa oparta o\u00a0agonist\u0119 receptora 5-HT7 (STEP7) &#8211;\u00a0II faza"}]},{"@type":"WebSite","@id":"https:\/\/if-pan.edu.pl\/#website","url":"https:\/\/if-pan.edu.pl\/","name":"Instytut Farmakologii PAN","description":"","publisher":{"@id":"https:\/\/if-pan.edu.pl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/if-pan.edu.pl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/if-pan.edu.pl\/#organization","name":"Instytut Farmakologii PAN","url":"https:\/\/if-pan.edu.pl\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/if-pan.edu.pl\/#\/schema\/logo\/image\/","url":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2023\/09\/logo_ifpan.svg","contentUrl":"https:\/\/if-pan.edu.pl\/wp-content\/uploads\/2023\/09\/logo_ifpan.svg","width":539,"height":139,"caption":"Instytut Farmakologii PAN"},"image":{"@id":"https:\/\/if-pan.edu.pl\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/if-pan.edu.pl\/#\/schema\/person\/6cf30bc4bc4eb96688ff1c7cbc34f8cc","name":"Magdalena Bartosik","url":"https:\/\/if-pan.edu.pl\/en\/institute\/employees\/magdalena-bartosik\/"}]}},"_links":{"self":[{"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/posts\/10804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/comments?post=10804"}],"version-history":[{"count":1,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/posts\/10804\/revisions"}],"predecessor-version":[{"id":10807,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/posts\/10804\/revisions\/10807"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/media\/8208"}],"wp:attachment":[{"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/media?parent=10804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/categories?post=10804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/if-pan.edu.pl\/en\/wp-json\/wp\/v2\/tags?post=10804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}